Redeye comments on the news that IRLAB has presented positive top-line data from the phase I study i...
Sales 0% and adj. EBIT +13% vs. ABGSCe Operating cash flow SEK 98m, vs ABGSCe SEK 6m Minor positive ...
Redeye shares its initial take on Kontigo Care’s Q4 2024 results, which showed sales and monthly rec...
Redeye retains its positive view on Lagercrantz following a Q3 report in-line with our estimates.
Redeye provides an initial comment on Addnode’s Q4 report, showing solid numbers in all three Divisi...
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial...
Redeye states that Enea showed solid sales growth while EBITDA margin were slightly below expectatio...
Redeye comments on further news from the all-important US market.
Redeye finetunes its forecasts for 2025 and beyond following Fortnox’s price increases.
Vitrolife continues stabilise its growth rate and is approaching high single-digit growth.
Redeye comments on Evolution’s Q4-results which were in line with our forecasts.
Redeye offers a preview of Doro's Q4 results set to be released on February 13.
Redeye comments on Embracer’s preliminary Q3-results which came in stronger than expected, driven ma...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, toget...
38% y-o-y sales growth for Catalyst in Q4'24e We leave our EBIT forecasts unchanged ahead of the rep...
